Kornimate/medical-research-clean huggingface dataset:
a retrospective study of the effects of different parameters on motor symptoms of pd in bilateral stn stimulation

Conditions: Parkinson's Disease

Summary: the purpose of this study is to assess the impact of different parameters (voltage, pulse width, frequency) of subthalamic nucleus (stn) deep brain stimulation (dbs) on motor symptoms in patients with parkinson's disease (pd).

in this observational study, we will retrospectively analyze the one-year follow-up data of 27 pd patients who received bilateral stn dbs in the first affiliated hospital of sun yat-sen university in the years 2008-2012. the data, including parameter settings and severity of motor symptoms indicated by unified parkinson's disease rating scale (updrs) part iii scores, was collected during the patients' annual visit to the hospital for reprogramming. a correlation analysis will be conducted to investigate the relationship between change of a specific parameter and the subsequent change of motor scores.

Eligibility criteria:
inclusion criteria: * pd patients treated with bilateral stn dbs in the first affiliated hospital in the years 2008-2012 exclusion criteria: * simultaneous participation in another clinical trial * dementia (mini mental state examination \< 26) * removal of dbs electrodes * loss to follow-up
frozen-thawed embryo transfer (ftet) cycle follow-up protocol (p06031)

Conditions: Infertility

Summary: the purpose of this follow-up study is to collect the outcome and safety of ftet cycles after the embryos are cryopreserved in p06029 (nct01144416). p06029 was a study in which a single injection of corifollitropin alfa (sch 900962) was compared with daily recombinant follicle stimulating hormone (recfsh) injections in women aged 35 to 42 years undergoing controlled ovarian stimulation (cos) prior to in vitro fertilization (ivf) or intracytoplasmic sperm injection (icsi).


Eligibility criteria:
inclusion criteria: * participant must have provided written informed consent for the trial. * participant must have cryopreserved embryo(s) in trial p06029 (nct01144416) of which at least one embryo is thawed for use in a subsequent ftet cycle.

Keywords: reproductive techniques, assisted follicle stimulating hormone, human fertilization in vitro
biomarkers for the early diagnosis, prediction, prognosis for colorectal cancers

Conditions: Colorectal Cancers

Summary: recent basic and clinical research on the circulating tumor cells (ctcs) in crc patients takes potential diagnostics, prognostics, and applications into consideration, especially the molecular detection of ctcs in peripheral blood. moreover, identification of therapeutic targets on ctcs and real-time monitoring of ctcs in cancer patients undergoing systemic therapy are the most important future clinical applications. ctcs measures may be useful to guide change in treatment decisions.

colorectal cancer (crc) is one of the most frequent malignancies and is also the third major cause of cancer-related death in taiwan, with over 11,000 new cases of crc were diagnosed and more than 4,400 taiwanese died from crc in 2008 (department of health). crc is regarded as the accumulation of acquired genetic and epigenetic changes causing disorders in cell growth, differentiation and apoptosis resulting in transformation of normal colonic epithelium to colon adenocarcinoma. recent basic and clinical research on the circulating tumor cells (ctcs) in crc patients takes potential diagnostics, prognosis, and applications into consideration, especially the molecular detection of ctcs in peripheral blood. moreover, identification of therapeutic targets on ctcs and real-time monitoring of ctcs in cancer patients undergoing systemic therapy are the most important future clinical applications. the investigators divide the current project into three dimensions to include all the biomarkers related to diagnostic, prognostic and predictive roles for the potential clinical implication. sub-project 1: prognostic validation and economic evaluation of biochips/biomarkers. sub-project 2: evaluation of biomarkers for tailored therapy. sub-project 3: identification and validation of novel biomarkers for early detection. after accomplishment of three sub-projects, a comprehensive network including early diagnostic, prognostic and predictive biomarkers/biochips for high-risk screening, postoperative surveillance, therapeutic strategies of crc patients will be formed.

Eligibility criteria:
inclusion criteria: 1. age \> 18 y/o 2. histological / pathologic and image study proved colorectal cancer 3. patients with adequate tissue for biomarkers analysis 4. patients voluntary sign informed consent exclusion criteria: * patients who are not met with either one of items which mentioned above.

Keywords: early diagnosis prediction prognosis
initiation of ovarian stimulation with recombinant-human fsh (bemfola®) in the late follicular phase

Conditions: Infertility, Female

Summary: a randomised controlled open-label clinical trial to compare the outcome parameters after ovarian stimulation using recombinant-human fsh (follicle stimulating hormone), starting on day 2 of the cycle versus start in the late follicular phase of the cycle.

objective: to determine whether late follicular stimulation using recombinant-human fsh has comparable outcomes to treatment using recombinant-human fsh in early follicular phase in a flexible gnrh (gonadotropin-releasing hormone) antagonist protocol, in oocyte donor patients. design: open label, phase 3 randomized trial using a two-arm design with 1:1 allocation ratio patients: oocyte donors (aged 18-36 years) intervention(s): reference group: start of ovarian stimulation with recombinant-human fsh (bemfola 225 iu daily) from day 2 of follicular phase onwards. initiation of gnrh antagonist (ganirelix, 0.25mg/day) on stimulation day 6 till day of trigger. investigational group: start of ovarian stimulation with recombinant-human fsh (bemfola 225 iu daily) from the late follicular phase of the menstrual cycle (evaluation trough ultrasound and hormonal assessment) onwards. start of gnrh antagonist (ganirelix 0.25mg/day) when serum lh (luteinizing hormone) \> 10 iu/l, till day of trigger. oocyte maturation trigger with gnrh agonist (0.2mg gonapeptyl) in both groups.

Eligibility criteria:
inclusion criteria: * oocyte donor patients * age from 18 to 36 years * bmi 19 to 35 * regular menstrual cycle length i.e. 24-35 days exclusion criteria: * patients with amh \<1.1 ng/ml and/or afc\<7 * patients with fnpo (follicle number per ovary) ≥ 19 and/ord amh \>5ng/ml * endometriosis grade 3-4 * oligo-amenorrhea * any untreated endocrine abnormality

Keywords: oocyte donor ovarian stimulation
determination of predictive clinical signs of effective rhizolysis using the dfl questionnaire.

Conditions: Rhizolysis; Diagnosis of Facet Joint Origin Lumbago

Summary: rhizolysis or lumbar thermocoagulation is a therapeutic proposal for certain types of chronic lower back pain that is resistant to medical treatment and outside the field of surgical indications. a previous study has selected functional and physical signs selected by analysts and a group of experts from the modified "delphi" prediction method. this study resulted in the creation of a questionnaire (dfl questionnaire) with 16 symptoms: 7 functional and 9 physical. the aim of this new study is to select the symptoms that have the best positive predictive value among the 16 symptoms, to predict a good result of rhizolysis, on the criterion of their mitigation or disappearance in case of effective rhizolysis.

the frequency of chronic lower back pain is a major economic and social problem. indeed, there are numerous solutions that can be offered to patients, but sometimes they are unsatisfactory as medical treatments are often insufficiently effective, surgical techniques are often invasive and indications can be limited. rhizolysis or lumbar thermocoagulation is a therapeutic proposal for certain types of chronic lower back pain that is resistant to medical treatment and outside the field of surgical indications. this technique, which is minimally invasive, is low-risk for patients and is widely used. however, few studies have shown its effectiveness, so the level of evidence is not enough to make this technique accepted as a standard. a previous study has selected functional and physical signs for joint involvement in lower back pain. this selection was made by analysts and a group of experts from the modified "delphi" prediction method. this study resulted in the creation of a questionnaire (dfl questionnaire) with 16 symptoms: 7 functional and 9 physical. the aim of this new study is to select the symptoms that have the best positive predictive value among the 16 symptoms, to predict a good result of rhizolysis, on the criterion of their mitigation or disappearance in case of effective rhizolysis.

Eligibility criteria:
inclusion criteria: * patient suffering from chronic lower back pain developing for more than 6 months and resistant to the medical treatments. * patients with an indication of lumbar rhizolysis for their chronic lower back pain with a facet component, the starting point of which corresponds to the l4l5 and/or l5s1 stages. * patient not objecting to their participation in the study. * subject registered with a social security scheme exclusion criteria: * adults under judicial protection * adult under guardianship or trusteeship * pregnant women * minors

Keywords: dlf questionnaire rhizolysis
efficiency of mirror therapy after carpal tunnel surgery

Conditions: Carpal Tunnel Syndrome; Physiotherapy; Rehabilitation

Summary: in the randomized controlled study with patients who appropriate the inclusion criteria are divided into two groups by simple drawing method. in the control group, the classical physiotherapy program is being applied when the post-operative immobilization period ended, mt is applied to the mirror group in addition to this treatment for 20 minutes and a total of 10 sessions in the immobilization period. patients who are scheduled for operation due to cts evaluated that pain (vas), sense (monofilament test), function (bctq, 9-hole peg test) before surgery, 3 weeks and 6 weeks after surgery.

purpose: the aim of this study is to investigate the efficacy of mirror therapy (mt). method: in the randomized controlled study with patients who appropriate the inclusion criteria are divided into two groups by simple drawing method. in the control group, the classical physiotherapy program is being applied when the post-operative immobilization period ended, mt is applied to the mirror group in addition to this treatment for 20 minutes and a total of 10 sessions in the immobilization period. patients who are scheduled for operation due to cts evaluated that pain (vas), sense (monofilament test), function (bctq, 9-hole peg test) before surgery, 3 weeks and 6 weeks after surgery. the spss 21.0 statistical program will be used in the data analysis of the study and the level of significance wiil be accepted as p\<0,05.

Eligibility criteria:
inclusion criteria: * carpal tunnel diagnosis and open surgery are planned, * having the ability to adapt to exercises, * voluntarily agree to participate in the work exclusion criteria: * with the forearm and hand trauma story * in the last 6 months, local corticosteroid injections to the treatment area have been performed * infection in the treatment area * having a deformity in hand * the presence of malignancy * being pregnant

Keywords: carpal tunnel syndrome mirror therapy postoperative rehabilitation physical therapy modalities median nerve
study to observe safety of xarelto in vte prophlylaxis after elective tkr (total knee replacement) or thr (total hip replacement)

Conditions: Prophylaxis, Thromboembolism, Venous; Total Knee Replacement; Total Hip Replacement

Summary: the primary objective of this study is to evaluate the safety of xarelto in the prophylaxis of vte in indian patients undergoing elective tkr/thr


Eligibility criteria:
inclusion criteria: * adult patients of either sex, undergoing elective thr/tkr, in whom, rivaroxaban is given for thromboprophylaxis * patients willing to give a written informed consent exclusion criteria: * exclusion criteria must be read in conjunction with the local product information * patients on ufh / lmwh therapy, fondaparinux and vitamin k antagonists are not eligible. * patients with history of hypersensitivity to active ingredients or excipient :cellulose microcrystalline, croscarmellose sodium, lactose monohydrate, magnesium stearate, sodium lauryl sulfate

Keywords: xarelto thromboembolism, venous orthopedic surgery factor xa inhibitor observational study
clinical study of toothpaste containing zinc lactate as compared to colgate cavity protection toothpaste.

Conditions: Gingivitis; Plaque

Summary: the objective of this six-month clinical research study is to evaluate the clinical efficacy of two dentifrices - toothpaste containing zinc lactate and colgate cavity protection toothpaste in reducing gingivitis and dental plaque in adults.


Eligibility criteria:
inclusion criteria: * subjects, ages 18-70, inclusive. * availability for the six-month duration of the clinical research study. * good general health. * minimum of 20 uncrowned permanent natural teeth (excluding third molars). * initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. * initial plaque index of at least 1.5 as determined by the use of the quigley and hein plaque index (turesky modification). * signed informed consent form exclusion criteria: * presence of orthodontic bands. * presence of partial removable dentures. * tumor(s) of the soft or hard tissues of the oral cavity. * advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). * five or more carious lesions requiring immediate restorative treatment. * antibiotic use any time during the one-month period prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition that prohibits eating or drinking for periods up to 4 hours. * history of alcohol or drug abuse. * pregnant or lactating subjects.
endurant bifurcated and aorto-uni-iliac (aui) stent graft system

Conditions: Abdominal Aortic Aneurysms

Summary: to demonstrate safety and effectiveness of the endurant stent graft in the treatment of abdominal aortic or aorto-uni-iliac aneurysms.

prospective, two-arm, non-randomized, multicenter clinical study enrolling subjects treated with the bifurcated stent graft in one arm and subjects treated with the aui in a second arm.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years old. 2. subject (or subject's legal representative) understands and voluntarily has signed and dated an informed consent document approved by the sponsor and by the institutional review board. 3. subject is able and willing to comply with the protocol and undergo follow-up requirements. 4. subject is a suitable candidate for elective surgical repair of aaa by as evaluated by american society of anesthesiologists (asa) physical status classification system i, ii, iii, or iv 5. subject has an abdominal aortic or aortoiliac aneurysm characteristics that meet protocol parameter 6. subject meets all the protocol anatomical criteria\* as demonstrated on contrast-enhanced ct or mra 7. subject has vascular dimensions in the range of sizes available for the endurant stent graft 8. subject has documented imaging evidence of at least 1 patent iliac and 1 femoral artery, or can tolerate a vascular conduit that allows introduction of the device. 9. subject's native vessel anatomy is more suited for the introduction and/ or deployment of an endurant uni-iliac stent graft system. exclusion criteria: 1. subject has a life expectancy \< 1 year 2. subject is participating in another investigational drug or device study 3. subject requires emergent aneurysm treatment 4. subject is a female of childbearing potential in whom pregnancy cannot be excluded. 5. subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to pre-treatment. 6. subject is morbidly obese (body mass index ≥ 40 kg/m2) or has other documented clinical conditions that severely inhibit radiographic visualization of the aorta.

Keywords: endurant stent graft system abdominal aortic aneurysms endovascular treatment
premedication efficacy of oral ketorolac and ketorolac/ acetaminophen on post treatment pain

Conditions: Irreversible Pulpitis

Summary: the aim of this study is premedication efficacy of analgesics on post endodontic pain. sixty-six healthy adult volunteers including criteria, are participating. the patients will be divided into 3 groups and will be randomly given one of pre medications including 1) 10 mg ketorolac, 2) 10 mg ketorolac plus 1000mg acetaminophen, and 3)placebo, 45 minutes before applying the injection. all patients will receive standard root canal treatment. patients will record their post treatment pain using a heft parker visual analog scale(vas). success will be considered as no or mild pain (vas≤54)with no need to take analgesic. data will be analysed using mann-u-whitney and kruskal-wallis tests.

the aim of this study is premedication efficacy of analgesics on post endodontic pain. sixty-six healthy adult volunteers with age ranged 18-65, non smoking or any medicine consumption, non pregnant or break feeding who haven't received any analgesic during 24 hours before the treatment, are participating. the patients will be divided into 3 groups and will be randomly given one of premedications including 1) 10 mg ketorolac, 2) 10 mg ketorolac plus 1000mg acetaminophen, and 3)placebo, 45 minutes before the treatment. all patients will receive a standard root canal treatment. patients will record their post treatment pain using a heft parker visual analog scale(vas). success will be considered as no or mild pain (vas≤54) with no need to take analgesic during 6, 12, 24 and 48 hours intervals following the treatment. data will be analysed using mann-u-whitney and kruskal-wallis tests.

Eligibility criteria:
inclusion criteria: * patients with age ranged 18-65 * without systemic diseases * without any medicine consumption * non smoking * non pregnant * non breast feeding * with asymptomatic irreversible pulpitis ( visual analog scale ≤ 54) in one mandibular molar that needs root canal treatment * without any medicine consumption or analgesic and sedation who understand and sign the vas and consent forms. exclusion criteria: -

Keywords: endodontic treatment non steroid pain pre medication
promotora-led intervention for metabolic and mental health

Conditions: PreDiabetes; Obesity; Metabolic Disease; Body Weight Changes; Diabetes Mellitus

Summary: evidence-based programs to prevent diabetes among high-risk individuals are less effective among those who also have mental health needs. this study involves developing and pilot testing the first adaptation of the landmark diabetes prevention program lifestyle intervention to simultaneously treat prediabetes and elevated mental health symptoms. this project has large potential to impact public health, given that more than half of the u.s. adult population has either of these conditions, and is at risk for developing comorbid diabetes and mental illness.

the overall goal of this study is to develop an effective and potentially scalable intervention to prevent diabetes in people with elevated mental health symptoms (ems) and prediabetes. this study focuses on latinos, a demographic group at particularly high risk for these related conditions. experience from the diabetes prevention program (dpp), and related translational studies, suggests that the evidence-based dpp lifestyle intervention is less effective among depressed individuals. the proposed promotora intervention for metabolic and mental health (prime2) will be the first adaptation of the dpp lifestyle intervention to simultaneously address mental health and prediabetes in a program delivered by promotoras, or community health workers.

Eligibility criteria:
inclusion criteria: * latino ethnicity * spanish fluency * age ≥18 years * bmi ≥25 kg/m2 * and "increased risk of diabetes" (ada diabetes risk score ≥5 as determined by 7-item questionnaire and/or hemoglobin a1c ≥ 5.7%) exclusion criteria: * hemoglobin a1c ≥ 6.5% * current or planned pregnancy during the study period * chronic conditions that could affect potential participants' ability to participate (osteoarthritis, heart disease, pulmonary disease requiring oxygen or daily bronchodilator use, and severe psychiatric disease) * medical comorbidities that could influence weight loss or weight gain (thyroid disease, cancer, and hiv) * medications that could affect weight or glucose metabolism (thiazide diuretics, β-blockers, and systemic glucocorticoids).
a prospective study of medical therapy against cryoballoon ablation in symptomatic recent onset persistent af

Conditions: Atrial Fibrillation

Summary: prospective trial comparing the efficacy and safety of cryoballoonablation (cba) to standardized medication for treatment of early onset persistent atrial fibrillation (af) without structural heart disease. the value of cba in these patients has never been studied; the endpoints for persistent patients are much easier than for paroxysmal patients. reduction in left atrial (la) size will be compared versus patients on drug therapy and versus failing patients.

the total af history should be shorter than 24 months. symptomatic patients can be included if they have had within the last year at least 2 episodes of documented af, lasting minimal 30 sec. one episode in the entire history should have lasted more than 48 h, requiring electrical or pharmacological cardioversion or stopped spontaneously after more than 7 days. all patients eligible for the study will sign informed consent, have an echocardiogram prior to inclusion to exclude severe left ventricular dysfunction, to rule out significant valve abnormalities, left ventricular hypertrophy and to assess the la volume and diameter. prior to randomization, and after inclusion it is suggested to the local investigators to perform an mri-scan or ct scan of the la and pulmonary veins (in both branches of the study ) in eligible patients to assess the anatomy and the left atrial volume. the results should not influence the strategy of treatment.

Eligibility criteria:
inclusion criteria: * \> 21 years and legally capable * first documentation or history of symptomatic af more than 30 sec within the last 2 years * twice af within the last year * one episode cardioverted after more than 48 hours or spontaneously terminated after more than 7 days * eligible for at least one first step drug therapy (sotalol, propafenone, or flecainide) and for amiodarone * left ventricular ejection fraction estimated \> 45% * la diameter \< 50 mm (parasternal short axis) and la volume less than 100 ml (apical view, area length method;) * chads2 ≤ 2 * failed aad strategy, or untreated with aad * no use of amiodarone in the previous 3 months (except iv or oral for 7 days) * informed consent exclusion criteria: * age \> 75 yrs * chf * ischemic heart disease as known in the history * (severe) left ventricular hypertrophy as shown on echo (ivsd or pwd \> 14 mm) * hyperthyroidism * congenital heart disease * hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, channelopathies * contra-indications to aad * long qt syndrome * received already adequately dosed all level 1 drugs (sotalol, propafenone, and flecainide) * pure (typical) atrial flutter as documented on one occasion

Keywords: atrial fibrillation cryoablation catheter ablation